Copies of letters sent to healthcare professionals in October 2013, to inform of new safety information and advice.
|
Date sent My husband used to start everyday with the product and it really works. Buy amoxicillin online no prescription! Generic drugs are required to have the same active ingredient, strength, dosage form, and route of administration as the brand name product.
|
Medicine |
Safety information |
|---|---|---|
|
October 2013 |
Short-acting beta agonists (terbutaline, salbutamol, hexoprenaline, ritrodine, fenoterol, isoxsuprine) Letter 1 Letter 2 Letter 3 |
Oral and suppository SABAs should not be used in obstetric indications. Parenteral SABA treatment duration should be limited to 48 hours maximum in the inhibition of premature labour. |
|
7 October 2013 |
Numeta G16%E |
Risk for hypermagnesaemia when administered to term newborn infants and children up to 2 years. HCPs should:
|
|
14 October 2013 |
Valdoxan/Thymanax (Agomelatine) |
Monitor liver function and do not use in people with high transaminase levels (>3 x ULN) or ≥75years. |
|
17 October 2013 |
Risperdal, Risperdal consta (risperidone), Invega (paliperidone), Xeplion (paliperidone palmitate) |
Risk of intraoperative floppy iris syndrome in people undergoing cataract surgery while taking α1a-adrenergic antagonists. |
|
23 October 2013 |
Jevtana ▼ (cabazitaxel) |
Reminder of reconstitution instructions to avoid overdose: pharmacies should review worksheets they use in the preparation of cabazitaxel. This is to ensure that they inform pharmacy staff to add the entire content of the solvent vial to the concentrate vial. |
|
28 October 2013 |
NovoMix30 Penfill and FlexPen (biphasic insulin aspart 30) |
Certain batches are being recalled due to incorrect insulin concentration. |
|
29 October 2013 |
IV iron preparations (Ferinject, Venofer, Ferrologic, Cosmofer, Monofer, Diafer) |
All IV iron preparations can cause serious hypersensitivity reactions. These may occur even when a previous administration has been tolerated. See http://tiny.cc/alvr5w for the Drug Safety Update article. |
|
31 October 2013 |
Mefloquine may induce serious neuropsychiatric disorders. Do not prescribe mefloquine for malaria chemoprophylaxis in people with past or present psychiatric disturbances. |
